Cyclosporine is a Small Molecule owned by Sun Pharmaceutical Industries, and is involved in 10 clinical trials, of which 5 were completed, 3 are ongoing, and 2 are planned.

Cyclosporine acts as calcineurin inhibitor. Calcineurin is an ubiquitous enzyme that is responsible for the release of pro-inflammatory cytokines. The drug candidate by inhibiting calcineurin prevents the release of pro-inflammatory cytokines.

The revenue for Cyclosporine is expected to reach a total of $4.8bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Cyclosporine NPV Report.

Cyclosporine is currently owned by Sun Pharmaceutical Industries.

Cyclosporine Overview

Cyclosporine (Cequa) is a polypeptide derivative, acts as an immunosuppressant. It is formulated as solution for drops for ophthalmic route of administration. Cequa is indicated to increase tear production in patients with moderate to severe keratoconjunctivitis sicca (Dry Eyes).

Cyclosporine is under development for the treatment of keratoconjunctivitis sicca in China.

Sun Pharmaceutical Industries Overview

Sun Pharmaceutical Industries (Sun Pharma) is a specialty pharmaceutical company that offers a wide range of pharmaceutical formulations such as branded generics and generic pharmaceuticals. The company’s portfolio includes products for the treatment of psychiatric, neurological, nephrological, gastroenterological, orthopedic and ophthalmologic diseases and disorders, and heart diseases. The company carries out product development, process chemistry, and manufacture of complex formulations, active pharmaceutical ingredients (APIs) and over-the-counter products. It offers drugs in various dosage forms such as tablets, capsules, injectables, inhalers, ointments, creams, and liquids. The company has manufacturing facilities in North America, Latin America, EMEA and Asia Pacific. Sun Pharma is headquartered in Mumbai, Maharashtra, India.

The company reported revenues of (Rupee) INR386,544.9 million for the fiscal year ended March 2022 (FY2022), an increase of 15.4% over FY2021. In FY2022, the company’s operating margin was 9.1%, compared to an operating margin of 7% in FY2021. In FY2022, the company recorded a net margin of 8.5%, compared to a net margin of 8.7% in FY2021. The company reported revenues of INR109,522.8 million for the second quarter ended September 2022, an increase of 1.8% over the previous quarter.

Quick View – Cyclosporine

Report Segments
  • Innovator (Non-NME)
Drug Name
  • Cyclosporine
Administration Pathway
  • Ophthalmic
Therapeutic Areas
  • Ophthalmology
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.